GPC3 CAR-T therapy (Fuda Cancer Hospital)

N/A

Report date: 2022/10/25 17:50:05

Base Information

Drug NameGPC3 CAR-T therapy (Fuda Cancer Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitors

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesFuda Cancer Hospital

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFuda Cancer Hospital

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A